SNU449_LIVER
HCC · Hepatocellular Carcinoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- HCC
- cancer_type_detailed
- Hepatocellular Carcinoma
- subtype
- —
- cancer_type
- HCC
- ccle_sample_id
- SNU449_LIVER
- synthetic_from_ccle
- true
- display_name
- SNU-449
- ccle_lineage
- liver
- ccle_lineage_subtype
- hepatocellular_carcinoma
- oncotree_code
- HCC
- cancer_type_detailed
- Hepatocellular Carcinoma
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | R211 | — | — | 0.777 |
| 2 | SRR8613758 | — | C | 0.742 |
| 3 | TCGA-AO-A0J5-01A-11R-A034-07 | — | A | 0.708 |
| 4 | TCGA-CV-7177-01A-11R-2016-07 | — | — | 0.689 |
| 5 | JHH4_LIVER | HCC | — | 0.678 |
| 6 | TCGA-A1-A0SH-01A-11R-A084-07 | — | A | 0.666 |
| 7 | TCGA-AR-A1AN-01A-11R-A12P-07 | — | A | 0.659 |
| 8 | 20040086.TNBC | — | C | 0.654 |
| 9 | TCGA-A1-A0SE-01A-11R-A084-07 | — | A | 0.651 |
| 10 | 4df6c488-ef2f-4019-a1b0-3a3624039be8 | — | — | 0.645 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.665 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.430 | Cobimetinib | — uncovered |
| APICAL_SURFACE | 0.412 | Temsirolimus | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.367 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.309 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.299 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.282 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.272 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.270 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.270 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.254 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.232 | Inavolisib | — uncovered |
| PEROXISOME | 0.216 | Idelalisib | — uncovered |
| COAGULATION | 0.210 | Binimetinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.131 | Inavolisib | — uncovered |
| MYOGENESIS | 0.129 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.088 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.081 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.069 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.061 | Inavolisib | — uncovered |